Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescita TherapeuticsTSX:CTX 20 Cash Ratio is 1.55 as of Mar. 2026, which is 15% below its 10-year median of 1.82. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 971 Drug Manufacturers companies, Crescita Therapeutics ranks better than 73.74% on this metric.
Crescita Therapeutics has a Cash Ratio of 1.55. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Crescita Therapeutics's Cash Ratio or its related term are showing as below:
TSX:CTX'
s Cash Ratio Range Over the Past 10 Years
Min: 1.19 Med: 1.82 Max: 8.85
Current: 1.55
During the past 12 years, Crescita Therapeutics's highest Cash Ratio was 8.85. The lowest was 1.19. And the median was 1.82.
TSX:CTX's Cash Ratio is ranked better than 73.74% of 971
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs TSX:CTX: 1.55
Crescita Therapeutics (TSX:CTX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a Cash Ratio of 1.55 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Crescita Therapeutics and its competitors. This is 15% below median its historical median of 1.82. Over the past decade, Crescita Therapeutics' Cash Ratio has ranged from 1.19 to 8.85. According to the industry distribution chart, Crescita Therapeutics ranks #255 out of 971 companies in the Drug Manufacturers industry, placing it in the top 26.3%.
Is Crescita Therapeutics' Cash Ratio too high?
Crescita Therapeutics' current Cash Ratio of 1.55 is 15% below median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 8.85. The Drug Manufacturers industry median Cash Ratio is 0.60. Crescita Therapeutics' value of 1.55 is 158.3% above this industry median. Based on the distribution chart, Crescita Therapeutics ranks #255 out of 971 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #255 out of 971 companies for Cash Ratio. This puts Crescita Therapeutics in the upper half of its industry. The industry median Cash Ratio is 0.60. Crescita Therapeutics' value of 1.55 is 158.3% above this benchmark. Historically, Crescita Therapeutics' own Cash Ratio has ranged from 1.19 to 8.85 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 0.60, Crescita Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current Cash Ratio of 1.55 is 158.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Crescita Therapeutics and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current Cash Ratio is 1.55, which is 15% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current Cash Ratio of 1.55. The current Cash Ratio is 1.55, which is 15% below median its 10-year median of 1.82 and 158.3% above the Drug Manufacturers industry median of 0.60. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Cash Ratio is 1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
